COMP <GO>
HALO vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Halozyme Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HALO 8
— ABBV 6
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: HALO
LAST: $130.91 (-0.21%) • MKT CAP: $14.89B
options-implied-move
6.50%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HALO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HALO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | 70.20% | +13.40 | HALO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.00% | 29.00% | -11.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.6x | 33.3x | +2.30 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 4.33% | 3.47% | +0.86 | HALO | /fcf-yield <GO> |
| Operating Margin | 33.60% | 24.60% | +9.00 | HALO | /operating-margins <GO> |
| Net Profit Margin | 22.70% | 6.90% | +15.80 | HALO | /net-margins <GO> |
| Revenue Growth (YoY) | 37.60% | 8.60% | +29.00 | HALO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.11 | 5.33 | -0.22 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 6.50% | 7.40% | -0.90 | HALO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 78.7 | 72.8 | +5.94 | HALO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.15 | -0.27 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.5x | 113.1x | -73.60 | HALO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.89B | $513.86B | -$498.97B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HALO REV | ABBV REV | HALO GROSS % | ABBV GROSS % | HALO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $61.16B | 83.6% | 70.2% | $644.6M | $17.82B |
| FY 2024 | $1.02B | $56.33B | 84.3% | 70.0% | $468.4M | $17.83B |
| FY 2023 | $829.3M | $54.32B | 44.0% | 44.0% | $351.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HALO // BETA 0.88
ABBV // BETA 1.15